At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 127 enrolled
Drug / intervention
Plerixafordrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies
Center for International Blood and Marrow Transplant Research·interventional·Posted Oct 1, 2012·Updated Sep 14, 2023
In Brief
A Phase 2 clinical trial evaluating Plerixafor for Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member and 7 related conditions. Completed, enrolled 127 participants across 12 sites.
Detailed Summary
This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelated Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease, Chronic Lymphocytic Leukemia
CountriesUnited States
CollaboratorsGenzyme, a Sanofi Company, Sanofi
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 2012
Enrollment StartMay 2013
Primary CompletionAug 2016
TodayJul 2026
First PostedOct 1, 2012
Enrollment StartMay 1, 2013
Primary CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.8 years ago
Interventions
Plerixafordrug